A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Dec 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Brain metastases; Neuroendocrine carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

19 Apr 2023 Updated Results (after 3 years of follow-up) assessing efficacy of neoadjuvant atezolizumab + chemotherapy in patients with resectable non-small cell lung cancer presented at the 114th Annual Meeting of the American Association for Cancer Research
12 Oct 2022 Status changed from active, no longer recruiting to completed.
14 Apr 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com